<PAGE>
                                                                    Exhibit 10.5

                                                                  EXECUTION COPY

                   DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

                           dated as of August 19, 1997

                                     Between

                              MEDCO RESEARCH, INC.

                                       and

                          DISCOVERY THERAPEUTICS, INC.

--------------------------------------------------------------------------------
Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as *. A complete version of this exhibit has been filed
separately with the Securities and Exchange Commission.
--------------------------------------------------------------------------------

<PAGE>

                                TABLE OF CONTENTS

<TABLE>
<CAPTION>
                                                                                                 Page
                                                                                                 ----
<S>                                                                                              <C>
SECTION 1. DEFINITIONS...........................................................................  1

         1.1      "Affiliate(s)".................................................................  1
         1.2      "Commercialization"............................................................  1
         1.3      "Co-Promoted Product"..........................................................  2
         1.4      "Contract Period"..............................................................  2
         1.5      "Discontinued Compound"........................................................  2
         1.6      "Effective Date of this Agreement".............................................  2
         1.7      "Exclusive License"............................................................  2
         1.8      "FDA"..........................................................................  2
         1.9      "FDA Approval".................................................................  2
         1.10     "First Commercial Sale"........................................................  2
         1.11     "Improvements".................................................................  2
         1.12     "IND"..........................................................................  2
         1.13     "Licensed Compounds"...........................................................  2
         1.14     "Licensed Patent Rights".......................................................  3
         1.15     "Licensed Processes"...........................................................  3
         1.16     "Licensed Processes Information"...............................................  3
         1.17     "Licensed Product".............................................................  4
         1.18     "NDA"..........................................................................  4
         1.19     "Net Sales"....................................................................  4
         1.20     "Non-Selected Compound"........................................................  5
         1.21     "Patent Costs".................................................................  5
         1.22     "Pharm Stress".................................................................  5
         1.23     "Product Development"..........................................................  5
         1.24     "Proprietary Information"......................................................  5
         1.25     "Research and Development".....................................................  6
         1.26     "Selected Compound"............................................................  6
         1.27     "Technology Transfer"..........................................................  6
         1.28     "Territory"....................................................................  6
         1.29     "Third Party Royalties"........................................................  6
         1.30     "United States"................................................................  6

SECTION 2. GRANTS, LICENSES AND FURTHER ASSISTANCE...............................................  6

         2.1      Exclusive License Grants.......................................................  6
         2.2      Provisions of Licensed Processes Information and Improvements..................  6
         2.3      Sublicenses....................................................................  7

SECTION 3. DRUG DEVELOPMENT......................................................................  7

         3.1      Steering Committee.............................................................  7
         3.2      Selected Compounds.............................................................  7
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                         <C>
         3.3      MRE Research and Development Commitment.................................   8
         3.4      Regulatory Filings......................................................   8
         3.5      Development Costs.......................................................   8
         3.6      Non-Selected Compounds..................................................   9
         3.7      Discontinued Compounds..................................................   9
         3.8      Limitations on DTI's Commercialization of Non-Selected and
                  Discontinued Compounds..................................................   9

SECTION 4. PAYMENTS AND ROYALTIES.........................................................  10

         4.1      Payments by MRE.........................................................  10
         4.2      Payments by DTI.........................................................  11
         4.3      Royalty Term............................................................  11

SECTION 5. DTI CO-PROMOTION RIGHTS; DISCONTINUED COMPOUNDS................................  12

         5.1      Option to Co-Promote....................................................  12
         5.2      Cost Sharing............................................................  12
         5.3      Product Development and Commercialization...............................  12
         5.4      Profit Sharing..........................................................  13
         5.5      Termination of Co-Promotion by DTI......................................  14
         5.6      Termination of Co-Promotion by MRE......................................  14

SECTION 6. ROYALTY RECORDS AND PAYMENTS...................................................  15

         6.1      Reports.................................................................  15
         6.2      Royalty Payments........................................................  15
         6.3      Withholding Taxes.......................................................  15
         6.4      Audit...................................................................  15
         6.5      Sublicensee Payments....................................................  16
         6.6      One Royalty.............................................................  16
         6.7      Sales to Affiliates and Sublicensees....................................  16

SECTION 7. PATENT PROSECUTION AND MAINTENANCE.............................................  16

         7.1      DTI Responsibility......................................................  16
         7.2      Abandonment.............................................................  17
         7.3      Payment of Patent Costs.................................................  17

SECTION 8. CONFIDENTIALITY................................................................  17

         8.1      Confidentiality.........................................................  17
         8.2      Duration................................................................  18

SECTION 9. REPRESENTATIONS AND WARRANTIES.................................................  18

         9.1      DTI Representations.....................................................  18
         9.2      MRE Obligations Conditional.............................................  20
</TABLE>

<PAGE>

<TABLE>
<S>                                                                                         <C>
         9.3      MRE's Representations...................................................  20

SECTION 10. ADVERSE PATENTS OR OWNERSHIP..................................................  20

         10.1     Third Party Patents.....................................................  20
         10.2     Co-Promoted Products....................................................  21

SECTION 11. INFRINGEMENT..................................................................  21

         11.1     Infringement Actions....................................................  21
         11.2     Rights During Pendency of Infringement..................................  22
         11.3     DTI Assignment of Pre-Effective Date Rights.............................  22

SECTION 12. INDEMNIFICATION...............................................................  23

         12.1     Indemnification.........................................................  23
         12.2     Procedure...............................................................  23
         12.3     Survival................................................................  24

SECTION 13. FORCE MAJEURE.................................................................  24

         13.1     Force Majeure...........................................................  24

SECTION 14. FIRST REFUSAL RIGHTS..........................................................  24

         14.1     MRE's First Refusal Rights..............................................  24

SECTION 15. TERM AND TERMINATION..........................................................  25

         15.1     Term....................................................................  25
         15.2     Termination for Cause...................................................  25
         15.3     Termination by MRE......................................................  25
         15.4     Consequences of Termination.............................................  25
         15.5     Survival................................................................  26

SECTION 16. MISCELLANEOUS PROVISIONS......................................................  26

         16.1     Notices.................................................................  26
         16.2     Modifications...........................................................  27
         16.3     Waiver..................................................................  27
         16.4     Assignment..............................................................  27
         16.5     Severability............................................................  27
         16.6     Governing Law...........................................................  28
         16.7     Headings................................................................  30
         16.8     Choice of Forum.........................................................  28
         16.9     Publicity...............................................................  28
         16.10    Entire Agreement........................................................  28
</TABLE>

<PAGE>

                   DEVELOPMENT AND COMMERCIALIZATION AGREEMENT

         This Agreement, made as of August 19, 1997, is by and between MEDCO
RESEARCH, INC. ("MRE"), a Delaware corporation having its principal place of
business at 85 T.W. Alexander Drive, P.O. Box 13886, Research Triangle Park,
North Carolina 27709, and DISCOVERY THERAPEUTICS, INC. ("DTI"), a Delaware
corporation having its principal place of business at 2028 Dabney Road, Suite
E-17, Richmond, VA 23230-3311.

         WHEREAS, DTI is the sole owner of the Licensed Patent Rights (as
hereinafter defined) and has developed and is the sole owner of the Proprietary
Information (as hereinafter defined) covering and/or relating to the Licensed
Processes (as hereinafter defined); and

         WHEREAS, MRE desires to obtain throughout the world the exclusive
license under the Licensed Patent Rights, Licensed Processes Information and
Improvements and DTI is willing to grant such license to MRE, all subject to the
terms and conditions set forth in this Agreement;

         NOW, THEREFORE, in consideration of the foregoing premises, which are
hereby incorporated into and hereby made a part of the terms and conditions of
this Agreement, and the mutual covenants recited hereinafter, it is agreed as
follows:

                                   SECTION 1.
                                   DEFINITIONS

         Whenever used in this Agreement, the following terms shall have the
meanings defined in this Section:

         1.1      "Affiliate(s)" means any person or entity that directly or
indirectly through one or more intermediaries controls, or is controlled by, or
is under common control with any other entity or person. For this purpose
"control" means the ownership or control of 50% or more of the outstanding
voting securities of a person or entity or, in the case of a partnership, the
power to appoint or elect 50% or more of the members of the board or management
or executive committee (or similar governing body) of the partnership, or the
power otherwise to direct or cause the direction of the management and policies
of such person or entity, whether through the ownership of voting stock or
similar rights, the holding of office, by contract or otherwise.

         1.2      "Commercialization" means the manufacturing, distribution,
marketing and sales activities contemplated by the Commercialization Plans
approved pursuant to Section 5.3.

<PAGE>

         1.3      "Co-Promoted Product" means a Licensed Product for which DTI
has, as set forth in Section 5.1, acquired co-promotion rights.

         1.4      "Contract Period" means the period beginning with the
Effective Date of this Agreement and ending on the date on which this Agreement
shall terminate in accordance with its terms.

         1.5      "Discontinued Compound" means either a Selected Compound as to
which MRE has filed an IND or an Co-Promoted Product as to which MRE has given
written notice to DTI of its decision to cease Research and Development or
Product Development.

         1.6      "Effective Date of this Agreement" means the date first
written above.

         1.7      "Exclusive License" means a license under the Licensed Patent
Rights and Licensed Process Information and Proprietary Information whereby
MRE's rights shall be sole and exclusive and shall operate to exclude all others
including DTI.

         1.8      "FDA" shall mean the governmental agency in each country in
the Territory responsible for granting in such Territory the approval to
manufacture and market therein a pharmaceutical product.

         1.9      "FDA Approval" means the approval granted by the FDA to
manufacture and market a pharmaceutical product on a commercial basis in each
country in the Territory.

         1.10     "First Commercial Sale" means the first bona fide sale of a
pharmaceutical product to a non-Affiliate third person, as evidenced by an
invoice to such third person, following FDA Approval in such country.

         1.11     "Improvements" means any findings, developments, discoveries,
inventions, additions, modifications, formulations or changes made by DTI or its
Affiliates and licensees during the Contract Period which are necessary or
useful to the development or commercialization of a Licensed Compound, Licensed
Product and/or a Licensed Process, including without limitation, new or improved
methods of administration, improved side effect profiles, new medical
indications and improvements in the synthesis or manufacturing processes.

         1.12     "IND" means an Investigational New Drug Application for
initiating clinical trials in the United States or any corresponding
application, registration or certification in any other country in the
Territory.

         1.13     "Licensed Compounds" means those compounds covered by the
Licensed Patent Rights.

                                        2

<PAGE>
         1.14     "Licensed Patent Rights" means:

                  (a)      All the patents and applications for patent that are
identified in Exhibit B, as well as all continuations, continuations-in-part,
divisions and renewals thereof, all patents which may be granted thereon, and
all reissues and extensions thereof, and all foreign counterparts; and

                  (b)      All applications for patent which may be filed any
time during the Contract Period covering Improvements, as well as continuations,
continuations-in-part, divisions and renewals thereof, all patents which may be
granted thereon, and all reissues and extensions thereof, and all foreign
counterparts, all to the extent such rights may be licensed by DTI or by any DTI
Affiliate to MRE without payment of consideration to any third party. If such
rights are subject to payment of consideration to a third party, they shall be
included in Licensed Patent Rights only if MRE undertakes in writing to make
payment of such consideration after full disclosure of the relevant
circumstances.

         1.15     "Licensed Processes" means the processes, methods and uses
covered by the Licensed Patent Rights.

         1.16     "Licensed Processes Information" means all technical and
business information, including without limitation all analyses, techniques,
technology, inventions, developments, know-how, experience, expertise, trade
secrets, processes, test results and other data (including raw data) and other
technical or business information which as of the Effective Date or at any time
during the Contract Period DTI or any DTI Affiliate owns, has the right to use
or otherwise possesses which pertain to or are useful in the evaluation,
development, testing, registration, manufacture, use or sale of Licensed
Compounds, Licensed Products and/or Licensed Processes, specifically including,
but not limited to, the following:

                  (a)      All available know-how, data (including raw data),
and other information concerning the stability, synthesis, manufacture,
chemistry, pharmacology, toxicology, efficacy and clinical use of Licensed
Compounds and/or Licensed Products for use in Licensed Processes;

                  (b)      All available information and data concerning the
effects, side effects and adverse reactions of Licensed Compounds and/or
Licensed Products in Licensed Processes which have been reported to or are known
by DTI;

                  (c)      Copies of all available papers relating to Licensed
Compounds and Licensed Products and/or Licensed Processes filed in and/or
received in patent offices in all

                                        3

<PAGE>
countries in which patent protection was, is or will be sought for Licensed
Compounds, Licensed Products and/or Licensed Processes; and

                  (d)      All other available know-how, data and information
necessary or useful in obtaining FDA Approval or relevant to either the safety
and efficacy or the compounding, manufacturing, packaging, marketing,
distribution and/or sale of Licensed Compounds and/or Licensed Products for use
in Licensed Processes.

         1.17     "Licensed Product" means any pharmaceutical product the
development, manufacture, use or sale of which would be prohibited but for the
Exclusive Licenses granted by DTI to MRE herein.

         1.18     "NDA" means a New Drug Application, Product License
Application or its equivalent in the United States or any corresponding
application in any other country in the Territory.

         1.19     "Net Sales" means the actual gross receipts derived by a party
or its Affiliates from sales by it to non-Affiliated third parties in the
Territory of the subject Licensed Product, less each and all of the following
deductions allowed or paid with respect thereto, where applicable: credits and
allowances for price adjustments, billing errors and the rejection or return of
the subject Product or Compound previously sold; rebates and cash discounts to
purchasers allowed and taken; commissions allowed or paid to brokers or agents;
transportation, insurance, handling, shipping charges and export packaging;
taxes, tariffs, customs, duties and other governmental charges levied on or
measured by the sale of the subject Product or Compound, whether absorbed by
such person or paid by the purchaser so long as such person's price is reduced
thereby, but not franchise or income taxes of any kind whatsoever; the amount of
Third Party Royalties; all normal and customary trade and quantity discounts,
Medicaid rebates, administrative fees to managed health care organizations,
governmental control sales rebates or charges, and chargebacks and reporting
rebates paid to wholesalers and other distributors; and sales, use or other
excise taxes or governmental charges levied on or measured by sales, including
value added taxes but excluding taxes based on income; provided, however, that
if any subject Product or Compound is sold in combination with other additional
therapeutically active ingredients, Net Sales for any such combination products
shall be computed by multiplying the Net Sales of such combination product, as
defined above, by a fraction, the numerator of which shall be the retail price
(if available, otherwise the fair market value) of the subject Licensed

                                        4

<PAGE>

Product contained in the combination product and the denominator of which shall
be the retail prices of such Licensed Product and all other therapeutically
active ingredients.

         1.20     "Non-Selected Compound" means (a) a Licensed Compound MRE has
not selected for clinical development during the Discovery and Development term
(as defined in Section 3.2), or (b) a Selected Compound as to which MRE has not
either (i) initiated animal toxicology studies within two (2) years of being
designed by MRE as a Selected Compound, or (ii) filed an IND within three (3)
years of such designation.

         1.21     "Patent Costs" means the legal, filing and other costs and
expenses of preparing, filing, prosecuting and maintaining all patent
applications and patents now or hereafter filed or issued, respectively, in the
Territory relating to the Licensed Patent Rights.

         1.22     "Pharm Stress" means the use of a pharmaceutical product as an
alternative to exercise in conjunction with stress cardiac diagnostic procedures
(e.g., stress thallium scintigraphy, stress echocardiography, etc.).

         1.23     "Product Development" means (i) the work conducted primarily
with the intent and for the purpose of formulating, and the entire development
process with respect to, a Licensed Product or Licensed Compound for use in a
Licensed Process, including the methods validation, the acquisition or synthesis
of raw materials, pharmacological tests and other activities in connection with
the manufacture and production of clinical trial material and finished
pharmaceutical dosages in commercial quantities, (ii) the preparation and
compilation of all the required data and information in a format appropriate and
ready for submission as "Chemistry, Manufacture and Control" data to the FDA,
(iii) document preparation and (iv) all other things customarily done in the
product development of pharmaceuticals by the holder of the exclusive right to
manufacture and market the subject pharmaceutical, excluding the payment of
Third Party Royalties and the work covered by Patent Costs.

         1.24     "Proprietary Information" means and collectively includes all
Licensed Processes Information (a) which is owned by DTI or which it has the
right to disclose to MRE as of the Effective Date of this Agreement or (b) which
is subsequently developed or acquired by DTI, its employees, consultants, agents
or Affiliates, in each case to the extent that such Information, as of the date
of disclosure to MRE, was not known to MRE or any of its Affiliates, disclosed
in published literature or available to the public.

                                        5

<PAGE>

         1.25     "Research and Development" means toxicology studies,
pre-clinical and clinical trials, IND and NDA filings with the FDA, applications
for trademark and all other things customarily done in the research and
development of a pharmaceutical, excluding the work covered by Patent Costs and
the payment of Third Party Royalties.

         1.26     "Selected Compound" means a Licensed Compound which MRE, by
written notice given to DTI at any time during the Discovery and Development
Term (as defined in Section 3.2), has selected as a candidate for clinical
development pursuant to Section 3.2.

         1.27     "Technology Transfer" shall mean the continuous providing by
DTI to MRE of Licensed Processes Information throughout the Contract Period.

         1.28     "Territory" means the entire world.

         1.29     "Third Party Royalties" means any royalties or other
compensation payable by a party to a third party with respect to developing,
making, having made, using or selling the subject Licensed Product or
Co-Promoted Product.

         1.30     "United States" means the United States of America, and its
territories and possessions.

                                   SECTION 2.
                     GRANTS, LICENSES AND FURTHER ASSISTANCE

         2.1      Exclusive License Grants. Subject to the terms and conditions
of this Agreement, DTI hereby grants MRE for itself and its Affiliates an
Exclusive License, with the right to sublicense, under the Licensed Patent
Rights and Licensed Processes Information and Improvements to develop, test,
make, have made, use, sell, offer to sell, import and export Licensed Products
in the Territory for use in Licensed Processes, subject to DTI's limited rights
of co-promotion as set forth in Section 5.

         2.2      Provisions of Licensed Processes Information and Improvements.
Within 15 days following the Effective Date of this Agreement, DTI will disclose
to MRE all the then extant Licensed Processes Information and Improvements.
Thereafter, DTI shall continue to disclose throughout the Contract Period all
additional Licensed Processes Information and Improvements within 15 days after
the development or discovery thereof by DTI or any DTI Affiliate or upon the
same becoming under the control or in the possession of DTI and its Affiliates.
All such disclosures shall be at DTI's sole cost and expense.

                                        6

<PAGE>

         2.3      Sublicenses. The right of MRE to grant sublicenses under
Section 2.1 of this Agreement is subject to the conditions that:

                  (a)      Each sublicense shall be consistent with all relevant
and applicable terms and conditions of this Agreement;

                  (b)      MRE shall remain responsible to DTI for all of the
obligations under this Agreement applicable to the sublicensee's activities;

                  (c)      Each sublicense shall provide for its termination
concurrent with termination of MRE's license rights from DTI; and

                  (d)      MRE shall provide DTI a complete copy of each
sublicense agreement granting rights to Licensed Products within thirty (30)
days of its execution, and DTI agrees to retain the contents thereof as a
confidential information as provided in Section 8 hereof.

                                   SECTION 3.
                                DRUG DEVELOPMENT

         3.1      Steering Committee. Promptly after the Effective Date of this
Agreement, DTI and MRE will each appoint two (2) representatives to serve on a
Steering Committee. One of the representatives of MRE shall be the Chairman of
the Steering Committee. Action of the Steering Committee shall be by majority
vote; provided, however, that any deadlock shall be resolved by the decision of
the Committee Chairman in his sole discretion. The purpose of the Steering
Committee shall be to receive from each party information with respect to all
material scientific, technical, regulatory and other matters falling within the
scope of Research and Development and Product Development. The Steering
Committee will meet periodically at such time and place as agreed to by both
parties. Each party shall bear its own meeting and travel expenses, and each
party may designate successor Steering Committee members on notice to the other
party.

         3.2      Selected Compounds. During the period from the Effective Date
of this Agreement to the * anniversary of such Effective Date (the "Discovery
and Development Term"), MRE shall have the sole and exclusive right, but not the
obligation, to clinically investigate and develop in any manner such of the
Licensed Compounds as it, in its sole discretion, shall select by written notice
to DTI given at any time or from time to time during the Discovery and
Development Term (the "Selected Compounds"). MRE shall provide copies of

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                        7

<PAGE>

such notices to the members of the Steering Committee. DTI will cooperate with
MRE in the Research and Development of the Selected Compounds as MRE shall
reasonably request; and except as otherwise expressly provided in this
Agreement, DTI shall not be obligated to perform any work or render any services
for MRE unless DTI in its sole discretion wishes to do so on such terms as it
and MRE shall mutually agree. During the Discovery and Development Term DTI will
not perform any Research and Development on any Licensed Compound except with
MRE's prior written approval.

         3.3      MRE Research and Development Commitment. During the Discovery
and Development Term, with respect to each Selected Compound MRE shall commit
such financial and other resources, if any, as MRE in its sole discretion deems
appropriate, and MRE shall not be required to expend any minimum amount of money
or effort on the Research and Development of, nor to file an IND or NDA with
respect to, any Selected Compound. MRE shall direct the Research and
Development, if any, of each Selected Compound in any manner, and with such
commitment of financial and other resources as it in its sole discretion deems
appropriate.

         3.4      Regulatory Filings. In the event MRE, in the exercise of its
sole discretion, determines to proceed with clinical development of a Selected
Compound, DTI at its sole cost and expense shall provide to MRE such available
information as MRE requests for filing an IND and, if further requested by MRE
after its determination in the exercise of its sole discretion to file an NDA,
an NDA with respect to any Selected Compound. In the event MRE requests that DTI
complete certain sections of the information packages needed for any such IND or
NDA filing, including but not limited to acute, subacute and chronic toxicology
studies, DTI, in its sole discretion, may agree to do such work on such terms as
it and MRE shall mutually agree. MRE shall be the sponsor of any IND and NDA
filed with respect to a Selected Compound.

         3.5      Development Costs. Subject to DTI's obligations to MRE in the
event DTI elects co-promotion rights in accordance with Section 5 hereof, MRE
shall pay all costs associated with the Research and Development and Product
Development of Selected Compounds and Licensed Products, including without
limitation all Research and Development and Product Development activities
rendered by DTI at MRE's request. When MRE shall identify appropriate
manufacturing sites, DTI at its sole cost and expense shall effectuate the
Technology Transfer and in so doing, DTI shall be required only to generate
extant information.

                                        8

<PAGE>

         3.6      Non-Selected Compounds. The rights granted to MRE under
Section 2.1 shall revert to DTI with respect to the following compounds
(hereinafter all such compounds shall be referred to as the "Non-Selected
Compounds"): (i) those Licensed Compounds which MRE did not select for clinical
development during the Discovery and Development Term and (ii) those Selected
Compounds with respect to which MRE has not (a) initiated animal toxicology
studies within two (2) years of being designated a "Selected Compound" and (b)
filed an IND within three (3) years of such selection.

         3.7      Discontinued Compounds. The rights granted to MRE under
Section 2.1 shall revert to DTI with respect to the following compounds
(hereinafter, such compounds shall be referred to as "Discontinued Compounds"):
Those Selected Compounds or Co-Promoted Products as to which MRE has given
written notice to DTI of its decision to discontinue Research and Development or
Product Development.

         3.8      Limitations on DTI's Commercialization of Non-Selected and
Discontinued Compounds.

                  (a)      DTI shall have the right to develop, make, use and
sell, with the right to sublicense, any Non-Selected Compound, Discontinued
Compound provided such Non-Selected or Discontinued Compound, in the opinion of
MRE, does not have any indication or field of use equivalent to that of a
Selected Compound, Licensed Product or Co-Promoted Product and will not compete
directly or indirectly with any Selected Compound, Licensed Product or
Co-Promoted Product (such as by being usable for any indication, whether or not
FDA Approved, which is the same as the FDA Approved field of use or indication
therefor).

                  (b)      Notwithstanding anything to the contrary contained
herein, if at any time MRE documents to DTI that a commercialized Non-Selected
Compound or Discontinued Compound is being used for a field of use or
indication, whether or not FDA Approved, which is the same as the FDA Approved
field of use or indication or for a Selected Compound, Licensed Product or
Co-Promoted Product, MRE shall engage a nationally recognized independent
accounting firm to estimate the amount of revenue MRE has lost and will lose in
the future as a result of such use. DTI agrees that MRE shall be entitled to
recover the amount thereof from DTI first through offsets against license fees,
milestones, royalties or other monies payable to DTI pursuant to this Agreement,
and secondly through royalties on sales of the subject Non-Selected or
Discontinued Compound and last, if the foregoing is insufficient, through a

                                        9

<PAGE>

reasonable mechanism to be mutually agreed by the parties. In addition to such
recovery, MRE shall be entitled to seek injunctive relief enjoining the further
manufacture and sale of the subject Non-Selected Compound or Discontinued
Compound, without the need for MRE to post a bond or other security.

                                   SECTION 4.
                             PAYMENTS AND ROYALTIES

         4.1      Payments by MRE. In consideration of the Exclusive License
granted to it hereunder, during the Contract Period MRE shall pay or cause to be
paid to DTI:

                  (a)      A non-refundable license fee of * on the Effective
Date of this Agreement;

                  (b)      * in quarterly installments of * commencing on
October 1, 1997;

                  (c)      * within sixty (60) days following filing of the
first IND for a Selected Compound for which there is no hold placed by the FDA
on initiating the clinical trial;

                  (d)      * within sixty (60) days following filing of the
first IND for a different Selected Compound for which there is no hold placed by
the FDA on initiating the clinical trial;

                  (e)      * within sixty (60) days following filing of the
first IND for one other different Selected Compound for which there is no hold
placed by the FDA on initiating the clinical trial;

                  (f)      * within thirty (30) days following the first dosing
of the first patient in a randomized controlled pivotal trial of a Selected
Compound;

                  (g)      * within thirty (30) days following the first FDA
Approval of an NDA for a Selected Compound;

                  (h)      Subject to the provisions of Section 10.1(b), for
sales by MRE or a MRE Affiliate when MRE or a MRE Affiliate sells a Licensed
Product in a country in the Territory where there are Licensed Patent Rights, a
royalty of * of Net Sales; and

                  (i)      Subject to the provisions of Section 10.1(b), for
sales of a Licensed Product by a MRE sublicensee or a MRE Affiliate sublicensee
in countries in the Territory where there are Licensed Patent Rights, (1) * of
all license fees, milestone payments and royalties received by MRE or a MRE
Affiliate from its sublicensees for such sales or as consideration for Licensed
Product rights for all FDA Approved indications with the exception

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       10

<PAGE>

of Pharm Stress, and (2) * of the royalties received by MRE from its
sublicensees on their Net Sales of Licensed Products for which the FDA Approved
indication is Pharm Stress.

         4.2      Payments by DTI. DTI shall pay to MRE:

                           (i)      For sales of a Discontinued Compound in the
                  Territory by DTI or a DTI Affiliate, a royalty of * of Net
                  Sales; and

                           (ii)     For sales of a Discontinued Compound by a
                  DTI sublicensee or a DTI Affiliate sublicensee, * of all
                  license fees, milestone payments and royalties received by DTI
                  or a DTI Affiliate from its sublicensee for such sales or as
                  consideration for the right to sell such Discontinued Product.

         4.3      Royalty Term.

                  (a)      As to each country in the Territory, the period
during which MRE shall be obligated to make payments to DTI required by Section
4.1 relating to sales by it, its Affiliates or sublicensees of a Licensed
Product shall end upon expiration, lapsing or final holding of the invalidity,
unenforceability or noninfringement by a decision of a court or governmental
agency of competent jurisdiction from which no appeal can be or has been taken
within the time allotted for appeal of the last patent claim within the Licensed
Patent rights covering that Licensed Product which would be infringed within
that country by MRE or its Affiliate or sublicensee but for the Exclusive
License granted pursuant to this Agreement, or upon the admission of the holder
of such last claim that it is invalid or unenforceable through reissue,
disclaimer or otherwise. When the payment period ends as to any country pursuant
to this Agreement, it is understood and agreed that MRE, its Affiliates and
sublicensees, if any, may make, have made, use, sell and/or distribute such
Licensed Product in that country in perpetuity with no further obligation to
make any payments to DTI therefor.

                  (b)      As to each country in the Territory, the period
during which DTI shall be obligated to make payments to MRE required by Section
4.2 relating to sales by it, its Affiliates or sublicensees of a Discontinued
Product shall end upon expiration, lapsing or final holding of the invalidity,
unenforceability or noninfringement by a decision of a court or governmental
agency of competent jurisdiction from which no appeal can be or has been taken
within the time allotted for appeal of the last patent claim covering that
Discontinued Product, or upon the admission of the holder of such last claim
that it is invalid or unenforceable through reissue, disclaimer or otherwise.
When the payment period ends as to any country pursuant to this

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       11

<PAGE>

Agreement, it is understood and agreed that DTI, its Affiliates and
sublicensees, if any, may make, have made, use, sell and/or distribute such
Discontinued Product in that country in perpetuity with no further obligation to
make any payments to MRE therefor.

                                   SECTION 5.
                 DTI CO-PROMOTION RIGHTS; DISCONTINUED COMPOUNDS

         5.1      Option to Co-Promote. Subject to the last sentence in this
Section 5.1, DTI shall have the option to elect to co-promote in the United
States each Licensed Product and thereby forego the receipt of, and release MRE
from its obligation hereunder to pay DTI, royalties on Net Sales in the United
States on such Product. In the event DTI wishes to exercise such option as to
any Licensed Product DTI must give to MRE written notice (a "Notice of
Election") of DTI's election to co-promote the specified Licensed Product in the
United States. Such Notice must be given within thirty (30) days following MRE's
filing of the IND therefor. Time shall be of the essence with respect to the
giving of such Notice. Anything in this Agreement to the contrary
notwithstanding, (a) DTI shall not have the right to sublicense any such
co-promotion rights and (b) DTI shall have no co-promotion option or rights with
respect to either the Licensed Compound identified on Exhibit A hereto as
WRC-0470 or any Licensed Product for use in Licensed Processes whose FDA
Approved indication is Pharm Stress.

         5.2      Cost Sharing. By duly giving a Notice of Election, DTI agrees
to pay to MRE, within forty-five (45) days after receipt of the invoice from
MRE, (a) * of the cumulated costs of Research and Development and Product
Development paid or incurred by MRE for the subject Co-Promoted Product prior to
MRE's receipt of the Notice of Election therefor, (b) on a quarterly basis going
forward, * of all costs therefore of (i) Research and Development and Product
Development judged by MRE in its sole discretion to be required for the U.S.
regulatory approval thereof and (ii) Commercialization in the United States.

         5.3      Product Development and Commercialization. Within thirty (30)
days following the delivery of DTI's Notice of Election for a Co-Promoted
Product, the parties will each appoint two (2) representatives as members of a
"Product Committee" (the "Product Committee"). Within three (3) months after
delivery of DTI's Notice of Election, such Product Committee will begin drafting
the initial development plan for the subject Co-Promoted Product (the
"Development Plan"). The parties shall request the Committee to complete such
Plan no later

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       12

<PAGE>

than three (3) months after the IND therefor is filed. The Committee will review
and, if warranted, revise such Plan for such Product every twelve (12) months
thereafter. The President of MRE shall have final decision-making authority over
the contents of each final Development Plan. Subject to the provisions of
Sections 5.5 and 5.6, all costs set forth in the Development Plans shall be
shared equally by the parties; and MRE shall invoice DTI therefor on a quarterly
basis, and DTI shall pay MRE the invoiced amount within forty-five (45) days
after the invoice date. MRE shall be the sponsor of every IND and NDA filed with
respect to a Co-Promoted Product. Thirty (30) days following the filing of the
NDA for such Product, the Product Committee shall become a Commercialization
Committee, the Development Plans shall become Commercialization Plans and the
President of MRE shall have final decision-making authority over the contents of
the Commercialization Plans; provided, however, that MRE shall be solely
responsible for the execution of the Commercialization Plan for each Co-Promoted
Product, including without limitation the manufacture, packaging, distribution
and booking of sales of each Co-Promoted Product and calculation of the Net
Profit with respect thereto pursuant to Section 5.4.

         5.4      Profit Sharing. Subject to DTI's performance of its
obligations pursuant to Sections 5.2 and 5.3 and the provisions of Section 5.5,
DTI shall have the right to receive from MRE * of the Net Profit from the sale
of each Co-Promoted Product in the United States, determined by MRE in
accordance with generally accepted accounting principles. The provisions of
Section 6 shall apply to such payments of Net Profit as if they were royalty
payments, except that MRE shall make such payments to DTI no later than 90 days
after the end of MRE's fiscal year. As used in this Section 5.4, "Net Profit"
means, in connection with sales of a Co-Promoted Product in the United States,
(i) all monies received by MRE or DTI or their respective Affiliates, less all
costs which are permitted in accordance with the terms of the Commercialization
Plan therefor approved pursuant to Section 5.3 and are actually incurred,
including without limitation manufacturing, regulatory, sales/marketing,
distribution, financing, travel, shipping and courier costs, and taxes other
than income taxes, and less all Third Party Royalties to the extent not included
in such Plan, and (ii) all other monies, including license fees, milestone
payments and similar monies of whatsoever description, received by MRE as
consideration for granting to a sublicensee rights to a Co-Promoted Product in
the United States.

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       13

<PAGE>

         5.5      Termination of Co-Promotion by DTI. DTI shall have the right
at any time to terminate the right, title and interest it acquired pursuant to
Section 5.1 in a Co-Promoted Product either (a) by failing to make, within
forty-five (45) days of the date due, any payment to MRE required by Section 5.2
or (b) by delivering to MRE written notice of termination. In the event of such
termination, DTI's co-promotion rights with respect to such Product shall
forthwith and forever cease and terminate, it shall not be entitled to any
refund or credit for any prior payments of costs of Research and Development,
Product Development or Commercialization with respect thereto nor shall it have
any liability to MRE for the one quarterly payment it failed to make or for
payment of any such future costs; provided, however, that anything to the
contrary in this Section 5.5 notwithstanding, such former Co-Promoted Product
shall be deemed a Licensed Product and MRE shall pay DTI royalties with respect
thereto in accordance with the provisions of Section 4.1.

         5.6      Termination of Co-Promotion by MRE. MRE shall have the right
at any time to terminate its right, title and interest in a Co-Promoted Product
by giving to DTI written notice of termination. In the event of such
termination, such Product shall be deemed a Discontinued Compound which DTI
shall have the sole right to develop, make, use and sell, with the right to
sublicense, provided such Compound, in the opinion of MRE, does not have any
indication or field of use equivalent to that of a Selected Compound and will
not compete directly or indirectly with any Selected Compound in development or
in the marketplace (such as by being usable for any indication, whether or not
FDA Approved, which is the same as the FDA Approved indication for a Selected
Compound). Anything to the contrary in this Section 5.6 notwithstanding, DTI
shall make payments to MRE with respect to such Compound in accordance with the
provisions of Section 4.2. MRE shall not be entitled to any refund or credit for
any prior payment of costs of Research and Development, Product Development or
Commercialization with respect thereto nor shall it have any liability to DTI
for payment of any such costs which are payable, regardless of when accrued,
following the date of its giving such notice of termination.

                                       14

<PAGE>

                                   SECTION 6.
                          ROYALTY RECORDS AND PAYMENTS

         6.1      Reports. Beginning sixty (60) days after the first calendar
quarter in which either Net Sales are first made of a Discontinued Compound or
Licensed Product or a party receives monetary proceeds from a sublicensee
requiring payment to the other party pursuant to Section 4, and sixty (60) days
after the end of any subsequent calendar quarter during the Contract Period, a
party shall deliver or cause to be delivered to the other party a written report
showing by country the sales of such Compound or Product or monetary proceeds so
received by it during the preceding quarterly period and showing the calculation
of Net Sales and the amount payable as royalties or otherwise pursuant to
Section 4. Concurrently with the submission of each such written report, the
party shall pay or cause to be paid to the other party the amount of royalties
or other monies shown to be due thereon, subject to the other provisions of this
Agreement.

         6.2      Royalty Payments. All royalty and other payments to be made by
one party to the other shall be paid in United States dollars in the United
States to such party at the address set forth in Section 16.1. For converting
into United States dollars a royalty accrued in another currency, the conversion
rate shall be the closing commercial buying rate of exchange for United States
dollars and such other currency as published in the Wall Street Journal, East
Coast Edition, as of the close of business on the last business day of the
applicable quarter of the royalty period for which payment is being made;
provided, however, that if for any reason conversion into United States dollars
cannot be made in a country in the Territory, payment may be made in the
currency of such country by deposit in the name of the payee in a bank and
account designated by it in such country.

         6.3      Withholding Taxes. All taxes assessed or imposed against or
required to be withheld from royalty payments due a party shall be deducted from
amounts payable hereunder and shall be paid on behalf of such party to
appropriate fiscal or tax authorities by the other party, which shall forward
the tax receipts it receives evidencing payment of such taxes to the party on
whose behalf such taxes were paid.

         6.4      Audit. MRE and DTI each shall, and shall cause their
Affiliates and sublicensees to, keep and maintain accurate records in sufficient
detail to enable the royalties payable hereunder to be calculated. Upon written
request from a party, the other party or its sublicensees

                                       15

<PAGE>

shall permit, upon reasonable prior written notice and during normal business
hours, a nationally recognized independent accounting firm within the "big six"
to have access, but not more often than once in any calendar year, to such
records within three (3) years after the royalty period to which such records
relate to verify the accuracy of the other party's royalty reports and payments
for such period. The party selecting and retaining such independent accounting
firm shall give concurrently to the other party a copy of the report of such
firm and shall cause such firm not to disclose to it or any other person or
entity any information except that which should properly be contained in a
royalty report required under this Agreement. The royalty-paying party shall
reimburse the other party for 50% of the reasonable costs of such audit if an
underpayment of royalties of more than 5% is revealed in the period audited.

         6.5      Sublicensee Payments. Each party agrees that any sublicensee
of the other party may pay, on behalf of such other party, any obligation of
such other party under Section 4 of this Agreement and that such payment shall
be received in lieu of payment by and in satisfaction of the obligation of such
other party; and any such sublicensee shall be bound by the other provisions of
this Section 6. Failure in payment by a sublicensee shall not excuse the
sublicensing party from its obligation to make the payments it is required to
make to the other party under Section 4.

         6.6      One Royalty. A royalty shall be paid only once on account of a
sale to a third party, even if the manufacture, use or sale is or shall be
covered by multiple Licensed Patent Rights.

         6.7      Sales to Affiliates and Sublicensees. No royalties shall be
payable on sales between a party and its Affiliates or permitted sublicensees.

                                   SECTION 7.
                       PATENT PROSECUTION AND MAINTENANCE

         7.1      DTI Responsibility. DTI shall instruct its patent counsel to
keep MRE currently advised in writing of all communications from the various
patent offices, provide MRE with copies of pending patent applications and all
related correspondence and consult with MRE, at MRE's reasonable request, and
consider MRE's comments and suggestions relative to the responses thereto. DTI
will promptly notify MRE in writing of and file for patent protection on the
Licensed Patent Rights and Improvements existing as of the Effective Date (if it
has not

                                       16

<PAGE>

previously done so) or arising during the Contract Period in the United States,
Canada, the European Union, and Japan. If MRE requests additional filings in any
other foreign jurisdictions, DTI shall make filings in such countries provided
MRE agrees in writing to pay all Patent Costs in such jurisdictions. DTI shall
use its best efforts to prosecute all patent applications it files pursuant to
this Agreement. DTI shall pay on a timely basis all fees and other costs and
expenses which are necessary to maintain in effect all patents which have issued
as the Effective Date of this Agreement or which may issue thereafter with
respect to the Licensed Patent Rights and Improvements.

         7.2      Abandonment. DTI shall not permit any applications for patent
within the Licensed Patent Rights or Improvements to become abandoned (unless
such application is being abandoned in favor of a continuation,
continuation-in-part or similar application) without giving MRE written notice
and an opportunity to assume prosecution of any such application for patent as
early as possible, which in no event shall be less than ninety (90) days prior
to the day on which it will become abandoned. DTI shall reasonably assist and
cooperate, at MRE's expense, in the prosecution of any patent applications as to
which MRE assumes the prosecution pursuant to this subparagraph and shall
execute such patent assignment documents as MRE shall request. MRE shall have
all of DTI's right, title and interest in and to all the Licensed Patent rights
in such country as are set forth in such application, and MRE and its Affiliates
and sublicensees shall not be obligated to pay DTI royalties on sales of any
Licensed Product covered by any patent as to which MRE has assumed the
prosecution pursuant to this Section 7.2.

         7.3      Payment of Patent Costs. DTI shall pay all Patent Costs except
as provided in Section 7.1 and where MRE has assumed the prosecution of a
patent.

                                   SECTION 8.
                                 CONFIDENTIALITY

         8.1      Confidentiality. MRE shall hold in confidence all Proprietary
Information which it obtains from DTI, DTI shall hold in confidence the contents
of all MRE sublicensing agreements it receives from MRE pursuant to Section 2.2
and all information it obtains from MRE relating to the Research and
Development, Product Development and Commercialization of Selected Compounds;
and DTI and MRE each shall hold in confidence all information they learn in
connection with the Research and Development, Product Development and

                                       17

<PAGE>

Commercialization of Co-Promoted Products. MRE may, however, disclose
Proprietary Information in a limited manner at MRE's sole discretion, if in
MRE's judgment such disclosure would be in the furtherance of the purposes of
this Agreement, to its Affiliates, sublicensees, governmental authorities,
consultants and/or agents, provided that in the case of Affiliates,
sublicensees, consultants and/or agents they agree in writing before disclosure
to be bound by the confidentiality obligations of this paragraph. Any
information which is properly included within Proprietary Information on the
date it is obtained by MRE shall cease to be regarded as such and MRE, its
affiliates and sublicenses shall be released from the provisions of this
paragraph on the date when, through no fault or omission of MRE, its Affiliates
or sublicensees such information becomes (a) disclosed in published literature,
(b) otherwise available to the public, or (c) disclosed or received by MRE or
any of its Affiliates or sublicensees in good faith from a third party who has a
right to disclose the same.

         8.2      Duration. The obligations of confidentiality in Section 8.1
shall be in effect for five (5) years after the expiration of the last to expire
patent within the Licensed Patent Rights.

                                   SECTION 9.
                         REPRESENTATIONS AND WARRANTIES

         9.1      DTI Representations. DTI hereby represents and warrants to MRE
as follows:

                  (a)      DTI is the sole assignee of and has good and
marketable title in and to the Licensed Patent Rights and Proprietary
Information and has the complete and sole right to license them to MRE. No third
person has acquired, owns or possesses any right, title or interest in or to the
Licensed Patent Rights in the Territory, and DTI has not authorized any others
to practice the Licensed Patent Rights in the Territory. Exhibit B lists all
developments, patent applications filed and patents issued within the Territory
on or before the Effective Date of this Agreement within the Licensed Patent
Rights.

                  (b)      There are no patents owned by others and no trade
secret or proprietary rights of others known to DTI on the Effective Date which
would be infringed or violated by developing, making, using, selling, or
distributing the Licensed Products and/or Licensed Compounds for use in Licensed
Processes by MRE, its Affiliates and/or sublicensees anywhere in the world. The
Licensed Patent Rights have not been obtained through any activity, omission or
representation that would limit or destroy the validity of any one or more of
such Rights; and

                                       18

<PAGE>

DTI has no knowledge or information that would impact the validity and/or
enforceability thereof;

         (c)      There are no adverse actions, suits or claims pending against
DTI or anyone in privy with DTI in any court or by or before any governmental
body or agency with respect to Licensed Compounds, Licensed Products, Licensed
Processes, Licensed Patent Rights or Proprietary Information, and no such
actions, suits or claims have been threatened against DTI or anyone in privy
with it.

         (d)      MRE and/or any sublicensees shall not be obligated to make
payments of any kind to any person, firm, corporation or entity other than DTI
in connection with MRE's acquiring the Exclusive Licenses that have been granted
or that may be granted in Section 2 hereof, and DTI is not aware, as of the
Effective Date of this Agreement, of any third party to whom MRE is or may be
obligated to make payments of any kind in connection with MRE's, its Affiliates'
and/or any sublicensees' developing, making, having made, using, selling, and/or
distributing Licensed Products and/or Licensed Compounds for use in Licensed
Processes for as long as the licenses granted to MRE hereunder remain in effect.

         (e)      Neither DTI, any of its Affiliates or agents nor anyone acting
on its behalf, shall disclose Proprietary Information to third parties or commit
any other act or take any action whatsoever to adversely affect, compromise or
destroy the value of the Proprietary Information, Licensed Patent Rights or the
licenses granted hereunder.

         (f)      DTI is a corporation duly organized, validly, existing and in
good standing under the laws of the State of Delaware.

         (g)      DTI has the full legal right, power and authority without the
consent of any other person, to execute, deliver, consummate and perform this
Agreement, to grant licenses set forth herein and to carry out the transactions
contemplated hereby, and it has made no commitments or obligations to any third
party inconsistent herewith.

         (h)      This Agreement is the lawful, valid and legally binding
obligation of DTI, enforceable in accordance with its terms, except as
performance may be limited by bankruptcy, insolvency, rearrangement,
reorganization or similar debtor relief legislation affecting the rights of
creditors generally and subject to the application of general principles of
equity.

         (i)      The execution and delivery of this Agreement and the
performance of the transactions contemplated hereby shall not result in the
creation of any lien, charge, security

                                       19

<PAGE>

interest or encumbrance on the Licensed Patent Rights and are not prohibited by
and do not violate or conflict with the charter or bylaws of DTI, or any
contract or other instrument by which DTI is bound, or any law, regulation or
judgment to which DTI is subject.

         9.2      MRE Obligations Conditional. MRE's obligations pursuant to
this Agreement are conditioned upon the foregoing DTI representations and
warranties being true and correct as of the date hereof and at all other times
that MRE is obligated, or may become obligated, to make payments to DTI pursuant
to the terms of this Agreement.

         9.3      MRE's Representations. MRE hereby represents and warrants to
DTI as follows:

                  (a)      MRE is a corporation duly organized, validly,
existing and in good standing under the laws of the State of Delaware.

                  (b)      This Agreement is the lawful, valid and legally
binding obligation of MRE, enforceable in accordance with its terms, except as
performance may be limited by bankruptcy, insolvency, rearrangement,
reorganization or similar debtor relief legislation affecting the rights of
creditors generally and subject to the application of general principles of
equity.

                                   SECTION 10.
                          ADVERSE PATENTS OR OWNERSHIP

         10.1     Third Party Patents. In the event that in a country in the
Territory a third party claims either that an issued patent in which it has
rights contains patent claims covering Licensed Products, Improvements, Licensed
Compounds and/or Licensed Processes or that it has an ownership right or
interest in Licensed Patent Rights, Improvements or Proprietary Information, MRE
shall have the right, at MRE's sole election, either:

                  (a)      directly or indirectly through its Affiliates and
sublicensees, to suspend or stop manufacture, use and sale of Licensed Products
or development of Licensed Compounds for use in Licensed Processes under this
Agreement in such country and to stop all royalty and other payments due to DTI
under Sections 4.1(h) and (i) for such country upon giving DTI one (1) month's
notice; or

                  (b)      to continue to manufacture, use and/or sell Licensed
Products and/or Licensed Compounds for use in Licensed Processes directly or
through its Affiliates and sublicensees and stand suit for patent infringement
or against claims by a third party to

                                       20

<PAGE>

ownershiprights or interest in the Licensed Patent Rights, Improvements or
Proprietary Information, at its own risk and expense.

         In addition to the foregoing options of MRE, MRE shall have the right
to obtain a license for the subject country within the Territory from any such
third party on such terms as MRE, in its sole discretion, shall negotiate, and
in any such event MRE shall be entitled and permitted to offset against and
deduct from the royalties and other compensation payable to DTI under Sections
4.1(h) and (i) hereof with respect to sales in the subject country within the
Territory 100% of the Third Party Royalties which MRE, its Affiliates and/or
sublicensees shall become obligated to pay to said third party under such
license if the third party's patent claims cover the composition of matter of a
Licensed Product. Unused credits may be carried forward and offset against
subsequent payments to DTI under such Sections.

         10.2     Co-Promoted Products. In the event a third party's claims
described in Section 10.1 relate to a Co-Promoted Product, MRE shall have the
right to obtain a license from any such third party on such terms as MRE, in its
sole discretion, shall negotiate, and in any such event the royalties and other
compensation payable to such third party shall be shared equally by MRE and DTI.

                                   SECTION 11.
                                  INFRINGEMENT

         11.1     Infringement Actions. DTI and MRE shall promptly notify each
other of any infringement of the Licensed Patent Rights and/or unauthorized use
of any Licensed Compounds, Licensed Products, Co-Promoted Products or Licensed
Processes which may come to their respective attention. MRE shall have the sole
right to take whatever steps MRE, in its sole discretion, deems appropriate with
respect to such infringement and/or unauthorized use including, but not limited
to, granting a sublicense to the infringing party or instituting a suit and
ultimately settling same. Should MRE determine to institute a suit, then it may
do so in its own name and/or the name of DTI and it may seek any and all
damages, whether they have accrued prior or subsequent to the Effective Date of
this Agreement. In the event that MRE fails to take any such steps within ninety
(90) days of the date on which it first became aware of the infringement and/or
unauthorized use involved, and if the Licensed Patent Rights at issue cover a
Licensed Product or Co-Promoted being actively developed or commercialized by
MRE at the

                                       21

<PAGE>

time, DTI shall then upon ninety (90) days written notice to MRE have the sole
right to institute suit, in its own name and/or in MRE's name, with respect to
the infringement and/or unauthorized use involved. With respect to any suit that
may be brought or instituted as provided in this Section, it is understood and
agreed that the party that brings or institutes such suit shall bear solely all
costs and expenses associated therewith and shall be entitled to retain and keep
(notwithstanding any other provisions of this Agreement to the contrary) any and
all sums received, obtained, collected or recovered whether by judgment,
settlement or otherwise, as a result of such suit; provided, however, that the
costs, expenses and recoveries in any such suit relating to a Co-Promoted
Product shall be shared equally by DTI and MRE. In addition, with respect to any
suit for infringement of the Licensed Patent Rights or unauthorized use of the
Licensed Compounds, Licensed Products, Co-Promoted Products or Licensed
Processes, the party that did not institute suit shall render all reasonable
assistance to the party that did institute suit at the suing party's expense,
including, but not limited to, executing all documents as may be reasonably
requested by the party that did institute suit.

         11.2     Rights During Pendency of Infringement. While acts of
infringement of Licensed Patent Rights are ongoing in a country in the
Territory:

                  (a)      If MRE or a MRE Affiliate or sublicensee has
instituted suit for such infringement, MRE and its Affiliates and sublicensees
will be relieved from the obligation to pay royalties to DTI for any and all
royalties for the making, use and/or sale of Licensed Products or Licensed
Compounds for use in Licensed Processes by it or on its behalf in that country
during the pendency of such action.

                  (b)      If DTI has instituted suit for such infringement in a
country and if the alleged infringer's product has attained more than * of
MRE's, its Affiliate's or sublicensee's sales in such country during any
calendar quarter, then no amount shall be payable by MRE, or its Affiliate or
sublicensee to DTI pursuant to Section 4.1 for sale of the Licensed Products
and/or Licensed Compounds for use in Licensed Processes in such country for so
long as the alleged infringer's product is sold therein.

         11.3     DTI Assignment of Pre-Effective Date Rights. DTI hereby
assigns to MRE DTI's right to institute suit for any infringement of the
Licensed Patent Rights and/or unauthorized use of the Proprietary Information
that occurred prior to the Effective Date of this Agreement, including the right
to retain and keep any and all sums received, obtained, collected or recovered

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

                                       22

<PAGE>

by judgment, settlement or otherwise as a result of such suit. DTI agrees to
inform MRE of all such prior infringement and unauthorized uses, their type and
duration and to assist MRE in prosecuting any action brought by MRE pursuant to
the provisions of this paragraph.

                                   SECTION 12.
                                 INDEMNIFICATION

         12.1     Indemnification. Each party shall indemnify, defend and hold
harmless the other party and its directors, officers, employees, and agents and
their respective successors, heirs, assigns and sublicensees, against any
liability, damage, loss or expense (including reasonable attorneys' fees and
expenses of investigation and litigation) incurred by or imposed upon the
persons to be indemnified or any one of them in connection with any claims,
suits, actions, demands or judgments arising our of the untruth, inaccuracy or
any breach of any representation, warranty, agreement, term, condition or
covenant made by such party in this Agreement. MRE also shall indemnify DTI and
its directors, officers, employees, and agents against any liability, damage,
loss or expense (including reasonable attorneys' fees and expenses of
investigation and litigation) incurred by or imposed upon the persons to be
indemnified or any one of them in connection with any claims, suits, actions,
demands or judgments arising out of any injury or death of persons or damage to
property resulting from the development or commercialization of Licensed
Products (but not Co-Promoted Products) by MRE except where such injury, death
or damage arose from the negligence or malfeasance of any entity or person to be
indemnified.

         12.2     Procedure. A person or entity seeking indemnification
hereunder (the "Indemnitee") shall notify the party from whom such
indemnification is sought (the "Indemnitor") within a reasonable time in writing
of any action, claim or liability in respect of which the Indemnitee intends to
claim such indemnification, provided that the failure to give timely notice to
the Indemnitor shall not release the Indemnitor from any liability to the
Indemnitee to the extent the Indemnitor is not prejudiced thereby. The
Indemnitor shall have the right, by prompt notice to the Indemnitee, to assume
the defense of such claim with counsel reasonably satisfactory to the Indemnitee
and at the sole cost of the Indemnitor, and if the Indemnitor so assumes such
defense, the Indemnitee may participate therein through counsel of its choice,
but at the sole cost of the Indemnitee. If the Indemnitor does not so assume the
defense of such claim, the Indemnitee may assume such defense with counsel of
its choice and at

                                       23

<PAGE>

the sole cost of the Indemnitor. The party not assuming the defense of any such
claim shall render all reasonable assistance to the party assuming such defense,
and all out-of-pocket costs of such assistance shall be for the account of the
Indemnitor. No such claim shall be settled other than by the party defending the
same, and then only with the consent of the other party, which shall not be
unreasonably withheld; provided that the Indemnitee shall have no obligation to
consent to any settlement of any such claim which imposes on the Indemnitee any
liability or obligation which cannot be assumed and performed in full by the
Indemnitor.

         12.3     Survival. This Section 12 shall survive expiration or
termination of this Agreement.

                                   SECTION 13.
                                  FORCE MAJEURE

         13.1     Force Majeure. Neither DTI nor MRE shall be liable to the
other for failure due to force majeure to perform any of its obligations under
this Agreement. As used in this Agreement, "force majeure" shall mean: Acts of
God; acts, regulations or laws of any government; war; civil commotion; strike,
lock-out, or labor disturbances; destruction of production facilities and
materials by fire, earthquake or storm; failure of public utilities or common
carriers; and any other cause or causes beyond the control of that party.

                                   SECTION 14.
                              FIRST REFUSAL RIGHTS

         14.1     MRE's First Refusal Rights. DTI shall give written notice to
MRE promptly after it acquires or develops any composition, method or process
relating to adenosine A2a agonists after the Effective Date of this Agreement.
MRE shall have the right of first refusal with respect to DTI's proposed grant
to any bona fide third party of any right, title or interest of DTI in or to
either any such composition, method or process or to any Non-Selected Compound
or Discontinued Compound (a "Grant of DTI Rights"). Accordingly, DTI shall give
written notice to MRE (the "Notice of First Refusal Rights") of the terms and
conditions (the "Third Party Terms") on which it has agreed, subject to MRE's
right of first refusal, to make any Grant of DTI Rights, which Notice shall
identify the proposed third party recipient of such Grant unless DTI is
prohibited from doing so by a confidentiality agreement or by law (the "Named
Third Party"). MRE shall have (10) business days to notify DTI that it wishes to
acquire the Grant of

                                       24

<PAGE>

DTI Rights on the Third Party Terms and an additional (30) business days
thereafter to enter into a definitive agreement with DTI on the Third Party
Terms. If MRE does not meet such conditions through no fault of DTI, DTI shall
be free to make a Grant of DTI Rights, but only to the Named Third Party and
only on the same terms and conditions as the Third Party Terms specified in the
Notice of First Refusal Rights. If either the actual Third Party Terms or the
Named Third Party varies from those specified in the Notice of First Refusal,
DTI shall be required to give to MRE a new Notice of First Refusal Rights, and
MRE shall have another opportunity to exercise its first refusal rights as
provided above. Any violation of this Section 14 shall entitle MRE to seek
injunctive relief, in addition to any other remedies available to MRE under this
Agreement or by law, without the need for MRE to post a bond or other security.

                                   SECTION 15.
                              TERM AND TERMINATION

         15.1     Term. This Agreement shall become effective on the date first
above written and shall continue until the expiration of the last to expire
patent in the Licensed Patent Rights, unless terminated earlier by one of the
parties hereto in accordance with its terms.

         15.2     Termination for Cause. A party may terminate this Agreement by
giving to the other party sixty (60) days prior written notice following:

                  (a)      the bankruptcy or the insolvency of the other party;
or

                  (b)      the breach of any material provision of this
Agreement by the other party if the breach is not cured within thirty (30) days
after written notice thereof to the party in default.

         15.3     Termination by MRE. MRE may surrender and thereby terminate
the license granted hereunder as to any Licensed Compound or Licensed Product
for use in a Licensed Process and as to any country in the Territory at any time
upon thirty (30) days prior written notice to DTI, and such termination shall
terminate all sublicenses granted under such license. MRE shall have no
financial liability or obligation to DTI as a result of such termination other
than the payment to DTI of royalties and other monies related to the subject
Licensed Compound or Product which accrued prior to the effective date of such
termination.

         15.4     Consequences of Termination. Termination, expiration,
cancellation or abandonment of this Agreement through any means and for any
reason shall not relieve the

                                       25

<PAGE>

parties of any obligation accruing prior thereto and shall be without prejudice
to the rights and remedies of either party with respect to any antecedent breach
of any of the provisions of this Agreement. Notwithstanding any other provision
of this Agreement, neither party shall be liable to the other for any
consequential, incidental, special or indirect damages whatsoever. Upon
termination of this Agreement, MRE shall transfer and assign to DTI any and all
data, information, regulatory filings and other information in MRE's possession
pertaining to Licensed Compounds, Licensed Products and Licensed Processes.

         15.5     Survival. In the event of termination or expiration of this
Agreement for any reason, the provisions hereof relating to confidentiality and
indemnification shall survive, and each party shall remain obligated to pay to
the other all monetary obligations hereunder which accrued prior to the
effective date of termination. In the event of termination of this Agreement for
any reason, MRE and its Affiliates and its sublicensees shall have the right to
sell any inventory of Licensed Products remaining after the effective date of
such termination, providing royalties are paid to DTI which otherwise would be
payable during the term of this Agreement.

                                   SECTION 16.
                            MISCELLANEOUS PROVISIONS

         16.1     Notices. All notices hereunder shall be in writing and shall
be delivered personally or mailed by registered or certified mail, postage
prepaid, or by electronic facsimile or delivery service for which receipt is
given, to a party at the following address:

                  in case of MRE, to:

                           Medco Research, Inc.
                           85 T.W. Alexander Drive
                           P.O. Box 13886
                           Research Triangle Park, NC 27709
                           Attn: Roger D. Blevins, Ph.D., President
                           Facsimile No: (919) 549-7515

                  with a copy to:

                           Hofheimer Gartlir & Gross, LLP
                           633 Third Avenue
                           New York, NY 10017
                           Attn: Richard G. Klein, Esq.
                           Facsimile No: (212) 661-3132

                  and in the case of DTI to:

                                       26

<PAGE>

                  Discovery Therapeutics Inc.
                  2028 Dabney Road - Suite E-17
                  Richmond, VA 23230-3311
                  Attn: Donald A. McAfee, Ph.D., President
                  Facsimile No: (804) 358-2451

or such other address as a party hereafter shall furnish to the other party by
written notice given as herein provided. Such notice shall be effective upon
receipt if personally delivered, delivered by electronic means or delivery
service, or on the third business day following the date of mailing.

         16.2     Modifications. No waiver or modifications of any of the terms
of this Agreement shall be valid unless in writing and signed by an authorized
representative of both parties hereto or by the party against whom enforcement
thereof may be sought.

         16.3     Waiver. Failure by either party to enforce any rights under
this Agreement shall not be construed as a waiver of such rights nor shall a
waiver by either party of any breach of any provision hereof by the other party
be construed as constituting a continuing waiver of any succeeding breach of
such provision or as a waiver of the provision itself.

         16.4     Assignment. Neither party shall assign this Agreement or any
part hereof without the prior written consent of the other party, provided that
a party may assign any or all of its rights and obligations to its Affiliates.
The transfer or sale of substantially the entire business or assets of a party
to which this Agreement pertains, or merger or consolidation of a party with
another company, shall be deemed an assignment of this Agreement but shall not
require the prior consent of the other party. Any assignee shall assume all
obligations of its assignor under this Agreement. No assignment shall relieve
any party of responsibility for the performance of any accrued obligation which
such party then has hereunder.

         16.5     Severability. This Agreement is subject to the restrictions,
limitations, terms and conditions of all applicable laws, governmental
regulations, approvals and clearances. If any term or provision of this
Agreement shall for any reason be held invalid, illegal or unenforceable in any
respect by any court or tribunal of competent jurisdiction in a final
non-appealable order or an order from which the allotted time to appeal has
expired, such invalidity, illegality or unenforceability shall not affect any
other term or provision hereof and this Agreement shall be interpreted and
construed as if such term or provision, to the extent the same shall have been
held to be invalid, illegal or unenforceable, had never been contained herein.

                                       27

<PAGE>

         16.6     Governing Law. All matters affecting the interpretation,
validity, and performance of this Agreement shall be governed by the internal
laws of the State of New York, exclusive of its choice of law rules, but the
scope and validity of Licensed Patents in any specific country shall be governed
by the applicable laws of the country granting the patent in question.

         16.7     Headings. The titles of the Sections contained herein are for
convenience only and shall not be considered in construing the meaning or
interpretation of this Agreement or any of its terms.

         16.8     Choice of Forum. The parties hereby irrevocably submit to the
exclusive jurisdiction of any United States District court sitting in the City
of New York. No suit, action or proceeding arising out of or relating to this
Agreement shall be brought before or removed to any other court.

         16.9     Publicity. Unless agreed to by the other party, which
agreement will not be unreasonably withheld, no party shall originate or issue,
any publicity, news release or other public announcement, written or oral,
whether to the public press, its stockholders or otherwise, relating to the
execution or delivery of this Agreement or any amendment hereto or the
performance of any of its terms or said party's receipt of any monies hereunder,
save only such announcement as in the opinion of legal counsel to the party
making such announcement is required by law to be made. The party making such
announcement shall give the other party a reasonable opportunity to review such
announcement before it is made. The parties acknowledge that MRE and DTI each
may file this Agreement with any governmental agency having jurisdiction over
the respective party in such matters and requiring the filing of this Agreement
with such governmental agency pursuant to applicable regulations.

         16.10    Entire Agreement. Neither party has relied or will rely on any
representation or agreement of the other except to the extent set forth herein,
and neither party shall be bound by or charged with any oral, written or implied
agreements, representations, warranties, understandings, commitments or
obligations not specifically set forth herein. This Agreement, together with the
exhibits hereto, constitute the entire agreement between the parties relating to
the Licensed Compounds, Licensed Products, Co-Promoted Products and Licensed
Processes, and all previous correspondence, agreements or arrangements between
the parties, written or oral, relating thereto, including without limitation
their prior confidentiality agreements, are hereby canceled and superseded.

                                       28

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed by their respective duly authorized officers the day and year first
above written.

MEDCO RESEARCH, INC.                          DISCOVERY THERAPEUTICS, INC.

By:   /s/ Roger D. Blevins                    By:   /s/ Donald A. McAfee
   -----------------------------------           ----------------------------

Title:    President                           Title:    President

Date:__________________________________       Date:___________________________

                                       29

<PAGE>

                                    Exhibit A
                           Discovery Therapeutics Inc.
                       Adenosine A\\2A\\ Agonist Agonists
                    Proprietary Compound Library July 1, 1997
*

--------------------------------------------------------------------------------
* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
--------------------------------------------------------------------------------

<PAGE>
                                                                  EXECUTION COPY

                                    EXHIBIT B
                           DISCOVERY THERAPEUTICS INC.
                 ADENOSINE A(2A) AGONIST PROGRAM PATENT SUMMARY
                            U.S. AND FOREIGN FILINGS


DTI DOCKET NO. W-0467


     Title: 2-Aralkoxy and 2-Alkoxy Adenosine Derivatives as Cardiac
            Vasodilators and Antihypertensive Agents

      Country    Application No.   Filing Date          Status (Issue Date)
    ---------------------------------------------------------------------------
       U.S.       07/482,282         2/20/90       Granted: 5,140,015 (8/18/92)
    (Reissue)     08/098,180         7/26/93                 Allowed
    ---------------------------------------------------------------------------
    Australia      73255/91          2/14/91                 Pending
    ---------------------------------------------------------------------------
     Canada       2,074,853          7/29/92                 Pending
    ---------------------------------------------------------------------------
      EPO        91-904813.2         2/14/91                 Pending
    ---------------------------------------------------------------------------
     Japan        505571/91          2/14/91                 Pending
    ---------------------------------------------------------------------------

DTI DOCKET NO. W-0497

     Title: 2-Hydrazoadenosines and Their Utility for the Treatment of Vascular
            Conditions

      Country    Application No.   Filing Date          Status (Issue Date)
    ---------------------------------------------------------------------------
       U.S.       07/873,440         4/24/92       Granted: 5,278,150 (1/11/94)
    ---------------------------------------------------------------------------
     Canada        2093502            4/6/93                 Pending
    ---------------------------------------------------------------------------
      EPO        93-106460.4         4/21/93                 Pending
    ---------------------------------------------------------------------------
     Japan       116663/1993         4/21/93                 Pending
    ---------------------------------------------------------------------------

DTI DOCKET NO. W-0502

     Title: Diagnostic Uses of Hydrazinoadenosines

      Country    Application No.   Filing Date          Status (Issue Date)
    ---------------------------------------------------------------------------
      U.S.       08/119,774         9/10/93       Granted: 5,477,857 (12/26/95)
    ---------------------------------------------------------------------------
      PCT*      PCT/US94/08847       8/5/94                  Pending
    ---------------------------------------------------------------------------
      *designates Australia, Canada, Japan, EPC countries

DTI DOCKET NO. W-0511

     Title: Compositions and Methods for the Prevention of Restenosis following
            Revascularization Procedures

      Country    Application No.   Filing Date          Status (Issue Date)
    ---------------------------------------------------------------------------
      U.S.      To Be Assigned      6/18/97                  Pending
    ---------------------------------------------------------------------------
      PCT         To Be Filed         --                       --
    ---------------------------------------------------------------------------